Mamedica® – the UK’s fastest-growing medical cannabis clinic, has partnered with Cantourage UK to launch the first of its own-branded products in the UK. The clinic confirmed that its first two strains of Mamedica® branded cannabis flower is now available to current and prospective patients.
Cantourage UK has provided access to one of its premium cultivation partners; Miracle Valley which is a fully operational British Columbian-based licensed facility in Canada. The cultivator is recognised for its “craft growing” approach to producing high-quality medical cannabis grown in a controlled indoor environment. This partnership will enable the distribution of high-THC, non-irradiated medical cannabis flower to patients across a range of health conditions.
Since its launch in 2022, Mamedica has grown exponentially continuing its offer of unrivalled access to a wide range of quality cannabis-based prescription medicines including flower, tinctures, vape cartridges and capsules. Testament to its rapid growth and the increase in public demand and awareness of medical cannabis, the clinic has observed a staggering 700 per cent increase in patient numbers since the beginning of 2023 and forecasts continued expansion into next year.
The partnership between Cantourage U, Miracle Valley and Mamedica® marks a significant development for the UK cannabis industry, broadening the scope of international, high-quality medical cannabis products available to patients in need of symptom management and relief.
Jon Robson, CEO and founder of Mamedica®, comments:
“We are delighted to announce that our partnership with Miracle Valley has cleared UK customs and marks the launch of our first own-branded strains of Canadian THC-dominant cannabis to the UK market. This collaboration marks a significant milestone for Mamedica® as we continue to expand our offerings to provide patients with access to high-quality medical cannabis products.
“All of our strains at Mamedica® undergo rigorous quality control measures to ensure that our patients receive the best possible treatment options. This partnership not only widens the range of medical cannabis products available in the UK but also allows our clinicians to continue their dedication to patient safety and satisfaction. We have already started to begin prescribing the two strains and anticipate they will offer transformative benefits to our patients across a range of health conditions.”
Niall Ivers, Co-Founder and COO of Cantourage UK comments:
“We are proud to support Mamedica, a patient-led service, with its own-branded cultivars of cannabis-based medicines. This represents the first instance in which we’ve introduced a brand exclusively for a UK group. This partnership showcases Cantourage UK’s skill in uniting different stakeholders to ensure the utmost quality for patients and prescribers. We are very excited at the opportunity to platform Mamedica’s growth and look forward to seeing this partnership flourish”.
